Vision & Mission
ARCE therapeutics
Our Vision: Focus on the needs of patients to achieve the goals of effective treatment of diseases and reasonable medical expenses through our "innovative immune cell therapy". To make cellular gene therapy faster, cheaper, and better and to make them affordable and accessible to patients.
Our Mission: Transform the lives of patients with unmet medical needs through pursuing science in action, conquering adversity with resilience, teamwork in collaboration, and a commitment to excellence.
ARCE Therapeutics, Inc. is a global biotech company, established in 2020 to develop patented intellectual properties in immune cell & gene engineering technology. ARCE is developing first-in-class and best-in-class CAR-T/CAR-NK cell therapy products for the treatment of various forms of cancers, including hematological cancers and solid tumors. Through ARCE’s innovative immune cell therapy and commercialization development, ARCE provides state-of-the-art products of new generation CAR-T/CAR-NK cell therapy, to make cellular gene therapy faster, cheaper, and better and to make them affordable and accessible to patients.

ARCE is to Accelerate the Revolution in Cell Engineering
Striving for innovations of cancer therapeutics in Action, Resilience, Collaboration, and Excellence!
Action
Take action and responsibility in combating cancer with novel immunotherapies, such as CAR-T treatments, to transform patients’ lives.
Resilience
Harness patients’ own immune system against malignancies and to grant patients with resilience in fending off life-threatening diseases.
Collaboration
We collaborate with partners globally on merging various expertise and platforms to create one-of-a-kind cell therapies that will turn the tide against cancer.
Excellence
ARCE aims to generate best-in-class cell therapies with excellent safety, potency and durability profiles which will benefit more patients.

STRATEGIES AND GOALS OF ARCE THERAPEUTICS
ARCE is engaging in new drug development focusing on R&D of preclinical and phase I/II proof-of-concept, and establish external partnership with leading research institutes and bio-pharma companies to to carry out the following: (1)Out-licensing patents or model systems (2)Collaborating with large pharmaceutical companies to co-develop novel pipelines. (3)Out-licensing to or partnering with other companies on new pipelines. (4)M&A or IPO as an exit plan.
